Can Valsartan Be Given in End-Stage Renal Failure?
Valsartan can be used in patients with end-stage renal disease (ESRD), including those on dialysis, but requires careful monitoring for hyperkalemia, hypotension, and changes in residual renal function. The FDA label explicitly states that safety and effectiveness have not been established in severe renal impairment (GFR <30 mL/min/1.73 m²), but does not contraindicate its use, and no dose adjustment is required 1.
Guideline-Based Recommendations
Primary Evidence from Guidelines
ACE inhibitors and ARBs (including valsartan) are recommended for heart failure patients and have been shown to improve outcomes, with studies demonstrating equivalence of benefit between ACE inhibitors and the ARBs candesartan or valsartan 2.
ARBs are not contraindicated in ESRD or dialysis patients. The American Heart Association explicitly states that ACE inhibitors are not contraindicated in patients with end-stage renal disease and are used frequently in dialysis patients 2.
In dialysis patients with hypertension, ACE inhibitors or ARBs are positioned as second-line agents after beta-blockers and calcium-channel blockers, which have the strongest cardiovascular outcomes data 3.
FDA Labeling Guidance
No dose adjustment is required for mild (GFR 60-90) or moderate (GFR 30-60) renal impairment, but the FDA notes that safety and effectiveness in severe renal impairment (GFR <30 mL/min/1.73 m²) have not been established 1.
Monitor renal function periodically in patients whose renal function may depend on the renin-angiotensin system, and consider withholding or discontinuing therapy if clinically significant decreases in renal function occur 1.
Hyperkalemia risk is increased in patients with pre-existing renal impairment, and dosage reduction or discontinuation may be required 1.
Clinical Algorithm for Use in ESRD
Step 1: Assess Volume Status and Blood Pressure Control
- Optimize volume status first through adequate ultrafiltration and dietary sodium restriction (2-3 g/day) before initiating valsartan 3.
- Target predialysis BP <140/90 mm Hg while avoiding intradialytic hypotension 3.
Step 2: Consider Cardiovascular Indications
- For heart failure patients with ESRD, valsartan (or sacubitril/valsartan) may provide cardiovascular benefits including reduced hospitalization 4, 5.
- For hypertension without heart failure, prioritize beta-blockers or calcium-channel blockers as first-line agents 3.
Step 3: Initiate Valsartan with Monitoring
- Start at standard doses (80-160 mg daily) without dose adjustment 1.
- Monitor serum potassium closely before initiation and within 1-2 weeks, as hyperkalemia risk is substantially elevated in ESRD 1.
- Check blood pressure for excessive hypotension, particularly in volume-depleted patients 1.
- Assess residual renal function in peritoneal dialysis patients, as ARBs may help preserve residual kidney function 3.
Step 4: Long-Term Management
- Continue monitoring potassium at regular intervals, especially if concurrent potassium-sparing agents or supplements are used 1.
- Evaluate for symptomatic hypotension and adjust dry weight before reducing valsartan dose 3.
- For sacubitril/valsartan specifically, recent evidence suggests prolonged use (≥185 days) may reduce cardiovascular events, while short-term use (<75 days) increases risk 6.
Evidence Quality and Nuances
Supportive Research Evidence
Recent meta-analysis (2025) of 1,597 dialysis patients with hypertension showed sacubitril/valsartan significantly reduced systolic BP (-11.09 mm Hg) and diastolic BP (-4.37 mm Hg), with lower cardiovascular hospitalization risk (RR 0.63) 4.
Randomized controlled trial (2025) in dialysis patients demonstrated greater BP reduction with sacubitril/valsartan versus irbesartan, particularly in hemodialysis patients (-15.9/-2.4 vs -6.6/-1.1 mm Hg, p<0.05) 5.
Historical data (1999) showed valsartan in moderate-to-severe renal failure effectively lowered BP while leaving GFR unaltered, with decreased proteinuria 7.
Divergent Evidence
Experimental animal data (2026) comparing sacubitril/valsartan to valsartan in CKD showed valsartan produced more pronounced renoprotective effects, though sacubitril/valsartan achieved greater BP reduction 8.
Real-world cohort study (2025) from Taiwan found short-term sacubitril/valsartan use (<75 days) in HF+ESRD patients increased risks of AMI readmission (aHR 2.83), HF readmission (aHR 5.36), and CV death (aHR 2.27), but prolonged use (≥185 days) trended toward protection 6.
Critical Pitfalls to Avoid
Do not initiate valsartan until volume status is optimized, as volume depletion dramatically increases acute renal failure risk 2, 1.
Do not combine valsartan with ACE inhibitors due to heightened hyperkalemia and acute kidney injury risk without additional benefit 2, 3.
Do not use valsartan with polyacrylonitrile dialysis membranes due to anaphylactoid reaction risk 2.
Do not ignore hyperkalemia, which is more common and potentially life-threatening in ESRD patients; establish a monitoring protocol before initiation 1.
Do not assume sacubitril/valsartan is superior to valsartan alone in ESRD without heart failure, as comparative outcomes data remain limited and short-term risks may outweigh benefits 6.
Do not discontinue abruptly in heart failure patients even if mild renal function decline occurs, as mortality benefits may outweigh risks; instead, optimize volume status and reassess 2.